<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="700">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 31, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03601442</url>
  </required_header>
  <id_info>
    <org_study_id>CCTL019B2003I</org_study_id>
    <nct_id>NCT03601442</nct_id>
  </id_info>
  <brief_title>CTL019 Out of Specification MAP for ALL or DLBCL Patients</brief_title>
  <official_title>Managed Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia
      (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification
      leukapheresis product and/or manufactured tisagenlecleucel out of specification for
      commercial release.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this Managed Access Program (MAP) Treatment Plan is to provide access to
      CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL)
      patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel
      out of specification for commercial release where no overwhelming safety concerns has been
      identified for manufacture and release of the out of specification product.
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Acute Lymphoblastic Leukemia (ALL)</condition>
  <condition>Diffuse Large B-cell Lymphoma (DLBCL)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CTL019</intervention_name>
    <description>CTL019</description>
    <other_name>tisagenlecleucel</other_name>
    <other_name>Kymriah</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent must be obtained prior to any screening procedures or
             treatment assignment.

          -  Has a patient specific batch of CTL019 which is out of specification either due to out
             of specification incoming apheresis or final product not meeting commercial release.

          -  Not excluded from commercial manufacturing under the prescribing guidelines for their
             country

          -  Out of specification material has not been deemed to pose an undue safety risk to the
             patient

          -  Is suffering from a serious or life-threatening disease or condition

          -  Repeat leukapheresis is not feasible per the treating physician assessment

          -  Does not have access to a comparable or satisfactory alternative treatment

          -  Is not eligible for participation in any of the IMP's ongoing clinical trials or has
             recently completed a clinical trial that has been terminated and, after considering
             other options, the clinical team has determined that treatment is necessary and there
             are no other feasible alternatives for the patient

          -  Meets any other relevant medical criteria for compassionate use of the investigational
             product

          -  Is not being transferred from an ongoing clinical trial for which they are still
             eligible

        Exclusion Criteria:

          -  Product can be commercially manufactured per the specification of the country in which
             treatment will occur.

          -  Patients who are able to repeat leukapheresis.

          -  Evidence of CD19 negative disease

          -  HIV positive patients

          -  Patients with active replication of Hep B or active or latent Hep C

          -  History of hypersensitivity to any drugs or metabolites of similar chemical classes as
             tisagenlecleucel.

          -  Uncontrolled active infection or inflammation

          -  History of unstable angina or MI within 6 months prior to screening

          -  Any medical condition identified by the investigator that may impact the assessment of
             the safety or efficacy outcomes in relation to study treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <verification_date>August 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2018</study_first_submitted>
  <study_first_submitted_qc>July 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>August 21, 2018</last_update_submitted>
  <last_update_submitted_qc>August 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <keyword>ALL</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Diffuse Large b-cell Lymphoma</keyword>
  <keyword>DLBCL</keyword>
  <keyword>Adult</keyword>
  <keyword>Relapse</keyword>
  <keyword>Refractory</keyword>
  <keyword>CTL019</keyword>
  <keyword>tisagenlecleucel</keyword>
  <keyword>Kymriah</keyword>
  <keyword>CART19</keyword>
  <keyword>CART</keyword>
  <keyword>CAR T cells</keyword>
  <keyword>Chimeric antigen receptor</keyword>
  <keyword>Manufacturing</keyword>
  <keyword>Expanded Access</keyword>
  <keyword>Out of Specification</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

